




616. ACUTE MYELOID LEUKEMIA: NOVEL THERAPY, EXCLUDING TRANSPLANTATION: POSTER II | DECEMBER 7, 2017

CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML

Kristopher Clark, PhD, Edward Ainscow, PhD, Adam Peall, Stuart Thomson, PhD, Andrew Leishman, PhD, Sullivan Elaine, PhD, Simak Ali, PhD, Raoul Coombes, MD, Anthony Barrett, PhD, Ash Kumar Bahi, PhD



Blood (2017) 130 (Supplement 1): 2645.


https://doi.org/10.1182/blood.V130.Suppl_1.2645.2645**Abstract**

CDK7 is considered an important new target for the treatment of human cancer as it controls the activity of key enzymes involved in cell cycle progression, including other cyclin dependent kinases such as CDK1, CDK2, CDK4 and CDK6. As a master regulator of transcription CDK7 also promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Both transcription and cell cycle regulation are dysregulated in Acute Myeloid Leukaemia (AML).

Here, we investigated the therapeutic potential of CT7001 (ICEC0942), a novel orally bio-available ATP competitive CDK7 inhibitor (Hazel et al 2017) in pre-clinical AML models. CT7001 potently inhibited the proliferation of several AML cell lines and patient derived AML cells in vitro, with IC50 values ranging from 0.15-2.6 μ M. Consistent with the inhibition of CDK7 in cells, treatment of the FLT3 internal tandem duplication (ITD) positive MV-4-11 cells with CT7001 led to a concentration dependent decrease in the phosphorylation of RNA polymerase II at Ser2, Ser5 and Ser7 as well as the phosphorylation of cell cycle signalling intermediates including CDK1, CDK2 and Rb1. Moreover, CT7001 treatment decreased the expression levels of c-Myc and the pro-survival factor Mcl-1 and induced the accumulation of cleaved PARP as a consequence of apoptosis. Finally, once daily oral administration of CT7001 to mice led to a sustained total growth suppression in a MV-4-11 xenograft model.

CT7001 is a potent, selective and orally bioavailable inhibitor of CDK7 that shows promise as a potential new treatment for AML.

Reference: Hazel et al. ChemMedChem. 2017 12(5):372-380 Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study

Figure[VIEW LARGE](#)[DOWNLOAD SLIDE](#)**Disclosures**

Clark: Carrick Therapeutics: Research Funding. **Ainscow:** Carrick Therapeutics: Employment, Equity Ownership. **Peall:** Carrick Therapeutics: Research Funding. **Thomson:** Carrick Therapeutics: Research Funding. **Leishman:** Carrick Therapeutics: Employment. **Elaine:** Carrick Therapeutics: Employment, Equity Ownership. **Ali:** Carrick Therapeutics: Consultancy, Equity Ownership, Patents & Royalties: Patent Inventor for CT7001. **Coombes:** Carrick Therapeutics: Consultancy, Equity Ownership, Patents & Royalties: Inventor on CT7001 patent. **Barrett:** Carrick Therapeutics: Consultancy, Equity Ownership, Patents & Royalties: Inventor on CT7001 patent. **Bahi:** Carrick Therapeutics: Employment, Equity Ownership.

Topics: administration, oral, apoptosis, barrett's esophagus, cancer, cdc2 protein kinase, cdk2 protein, human, cell cycle, cell cycle control, cell lines, c-myc genes

Author notes

* Asterisk with author names denotes non-ASH members.

© 2017 by The American Society of Hematology

Comments

0 Comments

Volume 130, Issue Supplement 1

December 7 2017

[Previous Article](#)[Next Article](#)**Potential Articles of Interest**

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
Borthakur et al., Blood, 2019

Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models
Andreeff et al., Blood

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)
Savona, Blood, 2013

PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
Li et al., Acta Pharmaceutica Sinica B, 2020

Combined inhibition of HDAC and DNMT1 induces p85 α /MEK-mediated cell cycle arrest by dual target inhibitor 208 in U937 cells
Ren et al., Chinese Chemical Letters, 2019

Virus inoculation and treatment regimens for evaluating anti-filovirus monoclonal antibody efficacy in vivo
Banadyga et al., Biosafety and Health, 2019

Powered by

TREND MD

I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). [Learn more](#)

[View Metrics](#)**Cited By**

Google Scholar

Email Alerts

Article Activity Alert

Latest Issue Alert